Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. 2004

Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Two hundred forty-eight human immunodeficiency virus (HIV)-positive and 496 HIV-negative subjects in Uganda were tested by HerpeSelect herpes simplex virus type 2 enzyme-linked immunosorbent assay (ELISA) and Western blotting to optimize the ELISA for use in this population. A higher index cutoff value was required for optimal sensitivity and specificity, and overall performance of the assay was not affected by HIV status.

UI MeSH Term Description Entries
D011933 Reagent Kits, Diagnostic Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use. Diagnostic Reagent Kits,Diagnostic Reagents and Test Kits,Diagnostic Test Kits,In Vitro Diagnostic Device,In Vitro Diagnostic Devices,In Vitro Diagnostic Medical Device,In Vitro Diagnostic Medical Devices,Kits, Diagnostic Reagent,Diagnostic Reagent Kit,Diagnostic Test Kit,Kit, Diagnostic Reagent,Kit, Diagnostic Test,Kits, Diagnostic Test,Reagent Kit, Diagnostic,Test Kit, Diagnostic,Test Kits, Diagnostic
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006558 Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. Genital Herpes,Herpes Simplex, Genital,Herpes Simplex Virus Genital Infection,Genital Herpes Simplex,Herpes, Genital
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014454 Uganda A republic in eastern Africa, south of SUDAN and west of KENYA. Its capital is Kampala. Republic of Uganda
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D018023 HIV Seronegativity Immune status consisting of non-production of HIV antibodies, as determined by various serological tests. HTLV-III Seronegativity,HIV Seronegativities,HTLV III Seronegativity,HTLV-III Seronegativities,Seronegativities, HIV,Seronegativities, HTLV-III,Seronegativity, HIV,Seronegativity, HTLV-III

Related Publications

Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
February 2005, Clinical and diagnostic laboratory immunology,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
May 1982, Journal of virological methods,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
August 1983, Journal of clinical microbiology,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
September 1984, Journal of clinical microbiology,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
March 1985, Journal of clinical microbiology,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
October 1977, The Journal of infectious diseases,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
December 1997, Journal of medical virology,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
February 1983, European journal of clinical microbiology,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
March 1998, Journal of clinical microbiology,
Oliver Laeyendecker, and Charla Henson, and Ronald H Gray, and Ruby H-N Nguyen, and Bobbi Jo Horne, and Maria J Wawer, and David Serwadda, and Noah Kiwanuka, and Rhoda Ashley Morrow, and Wayne Hogrefe, and Thomas C Quinn
October 1981, American journal of clinical pathology,
Copied contents to your clipboard!